Literature DB >> 6469496

Nafazatrom: in-vitro assessment of radiation and drug activity against animal and human cell lines.

J S Haas, C D Haas, G W Kyle.   

Abstract

The B-16 melanoma animal cell line and HEC-1A human endometrial cell line treated with Nafazatrom (NFZ) (5 mu/ml) and varying doses of ionizing radiation show a dose response curve of increased colony inhibition with increasing radiation dose. The B-16 line consistently demonstrated enhanced colony inhibition when NFZ was added prior to radiation. This colony inhibition by NFZ was not seen in the HEC-1A cell line. No adverse effect, i.e., increased tumor colony growth, was evident when NFZ and radiation were combined. This study suggests that ionizing radiation can be combined with NFZ without adverse effect on the cell killing effects of either modality.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469496     DOI: 10.1007/bf00173780

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  3 in total

1.  Stimulation of prostacyclin release from vessel wall by Bay g 6575, an antithrombotic compound.

Authors:  J Vermylen; D A Chamone; M Verstraete
Journal:  Lancet       Date:  1979-03-10       Impact factor: 79.321

2.  Nafazatrom: clonogenic in-vitro assessment of activity against human malignancies.

Authors:  C D Haas; G W Kyle; J D Crissman; M F Schaldenbrand
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

3.  Prostacyclin: a potent antimetastatic agent.

Authors:  K V Honn; B Cicone; A Skoff
Journal:  Science       Date:  1981-06-12       Impact factor: 47.728

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.